Released Nov 13, 2023, after the close
10-Q filed Nov 13, 2023, 44 days after period end · 0000950170-23-063037
Q3 2023 · 10-Q
Revenue$16.92M$16.92M −32.7% vs Q3 2022+62.5% vs Q2 2023
Net Income-$49.28M-$49.28M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.81-$0.81 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$44,014,000N/M
Operating Cash Flowderived-$33,502,000N/M
Margins · derived
Operating margin-260.1%−175.7 pt vs Q3 2022
Net margin-291.2%−213.7 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $16.92M | $25.15M | $8.52M | $17.82M |
| Net Income | -$49.28M | -$19.49M | -$30.90M | $17.14M |
| EPS Diluted | -$0.81 | -$0.37 | -$0.67 | $0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR